Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMOAZHY)

• Drug Name: Nemvaleukin alfa Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Ovarian cancer	2C73	Phase 3	[1]
Cutaneous melanoma	2C30	Phase 2	[2]

• Cross-matching ID: TTD Drug ID: DMOAZHY

Molecule-Related Drug Atlas

Drug(s) Targeting IL-1 receptor-like 2 (IL1RL2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Spesolimab	DM9FZYT	Psoriasis vulgaris	EA90	Approved	[4]
Imsidolimab	DMC3FOW	Generalized pustular psoriasis	EA90.40	Phase 3	[5]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
IL-1 receptor-like 2 (IL1RL2)	TTUS18T	ILRL2_HUMAN	Agonist	[3]

References

• [1] ClinicalTrials.gov (NCT05092360) A Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARTISTRY-7). U.S.National Institutes of Health.
• [2] ClinicalTrials.gov (NCT04830124) A Phase 2, Open Label, Multicenter, Cohort Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy in Patients With Advanced Cutaneous Melanoma or Advanced Mucosal Melanoma Who Have Previously Received Anti-PD-[L]-1 Therapy - ARTISTRY-6. U.S.National Institutes of Health.
• [3] Nemvaleukin alfa, a novel engineered IL-2 fusion protein, drives antitumor immunity and inhibits tumor growth in small cell lung cancer. J Immunother Cancer. 2022 Sep;10(9):e004913.
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] Imsidolimab, an anti-interleukin-36 receptor monoclonal antibody, for the treatment of generalized pustular psoriasis: results from the phase II GALLOP trial. Br J Dermatol. 2023 Jul 17;189(2):161-169.